Mr. Crispin M Sablan Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: Marianas Business Plaza, Ste 306-10, Chalan Kanoa, MP 96950 Phone: 670-287-1267 |
Christopher Gabredo Cabrera, MA, COUNSELING Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1 Lower Navy Hill Rd, Saipan, MP 96950 Phone: 670-234-8950 Fax: 670-233-8756 |
Maira Rios Arriola, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 6690 Commercial Bldg., Kagman Rd., Kagman Iii, Saipan, MP 96950 Phone: 670-256-5242 Fax: 670-256-5249 |
Ms. Jennifer Ada Furey, M.A., L.M.H.C. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 502316 Deskansa St Dan Dan Homestead, Saipan, MP 96950 Phone: 670-234-5103 |
Christine Strong, PA-C Counselor Medicare: Medicare Enrolled Practice Location: 1 Lower Navy Hill, Commonwealth Health Center, Saipan, MP 96950 Phone: 670-236-8308 |
News Archive
For the first time, a woman has given birth to two children after her fertility was restored using transplants of ovarian tissue that had been removed and frozen during her cancer treatment and then restored once she was cured.
Both environmental and genetic risk factors contribute to development of lung cancer. Tobacco smoking is the most well-known environmental risk factor associated with lung cancer. A Dartmouth research team led by Yafang Li, PhD, has conducted a study to display that gene-smoking interactions play important roles in the etiology of lung cancer.
CANTEL MEDICAL CORP., through its Mar Cor Purification subsidiary, has continued the expansion of its water purification and filtration segment by purchasing Texas-based Purity Water Company of San Antonio, Inc. Purity provides water treatment equipment and services for laboratory, industrial, medical, pharmaceutical and semiconductor customers in Texas and neighboring states. The acquired business had pre-acquisition revenues of approximately $3.0 million.
RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.
› Verified 8 days ago